Navigation Links
Vanda Pharmaceuticals Reports Second Quarter 2011 Results
Date:8/4/2011

ROCKVILLE, Md., Aug. 4, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced financial and operational results for the second quarter and six months ended June 30, 2011.

"We are pleased with our progress towards our vision of building a CNS specialty pharmaceutical company.  Fanapt® scripts in the U.S. continued to grow, and we have made advances towards the globalization of the franchise.  We are excited about the prospects of our tasimelteon programs in both Non-24 and major depression, which are currently underway," said Mihael Polymeropoulos, M.D., President and Chief Executive Officer.

Key Highlights:

  • Vanda recorded second quarter 2011 revenue of $7.4 million including royalties of $0.8 million. Second quarter sales of Fanapt® as reported by Novartis included a $2.7 million cumulative adjustment to gross to net sales reserves that resulted in approximately $270 thousand less in royalties to Vanda in the period.
  • Fanapt® prescriptions, as reported by IMS, reached 30,000 in the second quarter of 2011.  This represents a 17% increase over first quarter 2011 prescriptions.  
  • On July 22, 2011, the European Medicines Agency (EMA) notified Vanda that it had accepted for evaluation the Marketing Authorization Application (MAA) for oral iloperidone tablets.
  • Vanda announced commercialization agreements for two Latin American markets.  On July 11, 2011, Vanda entered into an exclusive license agreement with Probiomed S.A. de C.V. (Probiomed) for the commercialization of Fanapt® in Mexico.   On August 1, 2011, Vanda entered into an exclusive license agreement with Biotoscana Farma S.A. (Biotoscana
    '/>"/>

  • SOURCE Vanda Pharmaceuticals Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
    2. Vanda Pharmaceuticals Reports Third Quarter 2007 Results
    3. Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
    4. Vanda Presents Phase III Iloperidone Efficacy Data
    5. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
    6. Vanda Pharmaceuticals Provides Update on Iloperidone
    7. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
    8. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
    9. Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
    10. Vanda Pharmaceuticals Announces Expiration of Hart-Scott -Rodino Waiting Period for Exclusive License of Fanapt(TM)
    11. Vanda Pharmaceuticals Announces U.S. Patent Allowance for a Long-Acting Injectable Formulation of Fanapt(TM) (iloperidone) in the U.S.
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/29/2014)... Inc. (NYSE: CVD ) today reported results ... revenue was $639 million, representing 8.0% growth from the ... company reported earnings of $0.29 per diluted share in ... per diluted share of $0.95, up 21.5% over the ... impairment charges totaling $52.6 million, or $0.61 per share, ...
    (Date:7/29/2014)... July, 29  2014 ISPE—the International Society for ... John Bournas as President and CEO, succeeding ... leave the Society last fall.  Mr. Bournas takes ... the healthcare association industry as well as significant ... clear vision for the expansion of its global ...
    (Date:7/29/2014)... 2014  Roche (SIX: RO, ROG; OTCQX: RHHBY) launched ... (AACC) 2014 Clinical Lab Expo today by unveiling two ... Roche is partnering with customers to redefine the value ... every day that they,re looking for a partner to ... labs and offices," said Jack Phillips , president ...
    Breaking Medicine Technology:Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 2Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 3Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 4Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 5Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 6Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 7Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 8Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 9Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 10Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 11Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 12Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 13Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 14Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 15Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 16Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 17Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 18Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 19Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 20Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 21Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 22Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 23Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 24ISPE Hires Healthcare Association Exec as CEO 2ISPE Hires Healthcare Association Exec as CEO 3Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 2Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 3Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 4
    ... 20,000 doses of ABthrax will bring at least ... Feb. 2 Human Genome Sciences, Inc. (Nasdaq: ... has begun delivery of 20,000 doses of its ... U.S. Strategic National Stockpile for use in the ...
    ... Kroger Co. (NYSE: KR ) said today it ... cakes sold in its family of stores because the products ... the following names in the 31 states where Kroger operates ... Food 4 Less, Fry,s, King Soopers, Smith,s, Dillons, QFC, City ...
    Cached Medicine Technology:Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile 2Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile 3Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile 4Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile 5Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile 6Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile 7Kroger Recalls Peanut Butter Bakery Cookies and Select Cakes Due to Possible Health Risk 2Kroger Recalls Peanut Butter Bakery Cookies and Select Cakes Due to Possible Health Risk 3
    (Date:7/29/2014)... 2014 Paul Mata, CEO of ‘Create Indestructible ... in 30 Days” E-book. The e-book includes a myriad of ... extra cash. Examples include downloading and utilizing specific phone apps ... help people monetize the assets they didn't know they had ... can find in their garage. , After reading the ...
    (Date:7/29/2014)... (PRWEB) July 29, 2014 1Heart ... senior communities with focus on Brain Fitness Education ... in Ventura. Brain Fitness Program Director Tee Barr ... Aegis Memory Care unit and the Assisted Living ... Aegis Life Enrichment Director Christy Rozsa and Aegis ...
    (Date:7/29/2014)... (PRWEB) July 29, 2014 Daily Gossip ... well as all other disturbing symptoms that hemorrhoids commonly ... a researcher and natural medicine expert. , The ... lead to the elimination of symptoms such as itching, ... , Learn more about the H Miracle by visiting ...
    (Date:7/29/2014)... (PRWEB) July 29, 2014 The One Minute ... by Alison Freeman, an herbal medicine specialist. Alison Freeman wanted ... herpes condition. , People interested in finding out more ... and can download it, as it is currently available in ... variety of natural remedies and herbal medicine tips that can ...
    (Date:7/29/2014)... (PRWEB) July 29, 2014 Daily Gossip indicates ... new method was created for any sufferer who is looking ... , The author of the new program, Sarah Summer, says ... actually suffered from yeast infection, too. Actually, this is the ... for this problem. , The Natural Cure for ...
    Breaking Medicine News(10 mins):Health News:Create Indestructible Wealth Launches Innovative E-Book: “Realistic Ways to Make More Money in 30 Days” 2Health News:1Heart Caregiver Services Conducts Brain Fitness Education and Brings Tee Barr to Aegis Ventura 2Health News:1Heart Caregiver Services Conducts Brain Fitness Education and Brings Tee Barr to Aegis Ventura 3Health News:1Heart Caregiver Services Conducts Brain Fitness Education and Brings Tee Barr to Aegis Ventura 4Health News:H Miracle Review Exposes Natural Method to Cure Hemorrhoids 2Health News:One Minute to Herpes Cure Review Reveals Simplest Herpes Treatment 2Health News:Natural Cure for Yeast Infection Review Reveals Sarah Summer’s Healing Method 2
    ... to exchange innovative ideas, best practices and thought leadership, The ... global headquarters in Findlay, OH, brought together over one-hundred of ... of industries. , ... Findlay, OH ...
    ... now celebrating their 25th anniversary, selects Boondock Walker as their ... ... Cleveland, OH (PRWEB) May 27, 2009 ... Boondock Walker as their strategic partner in the ...
    ... national laboratories have worked together to develop a ... for pandemic influenza. The tool can help estimate ... the screening process, and so assess the risk ... nation. , Robert Brigantic, and colleagues at the ...
    ... intraepithelial neoplasia (HGPIN) carries a high predictive value ... in the open access journal BMC Urology ... extended core biopsy led to an initial diagnosis ... , Paras Singh and Francis Martin, from Lancashire ...
    ... - Product sales revenue ... loss narrows significantly,VANCOUVER, May 26 /PRNewswire-FirstCall/ - CRH Medical ... $1,735,890 for the three months ended March 31, 2009 ... 31, 2008. The Company reported Clinic operations revenue of ...
    ... Lung Cancer Alliance (LCA) hailed the US Court ... ruling that found tobacco companies guilty of fraud ... smoking.(Logo: http://www.newscom.com/cgi-bin/prnh/20081016/LCALOGO )The ... a 2006 federal court conviction of fraud and ...
    Cached Medicine News:Health News:The RightThing Brings Together Over 100 Top HR Execs for Thought Leadership and Collaboration 2Health News:The RightThing Brings Together Over 100 Top HR Execs for Thought Leadership and Collaboration 3Health News:Boondock Walker Elevates LMI with Innovative Strategic Communications 2Health News:Pandemic passenger screening 2Health News:CRH Medical reports Q1 2009 results 2Health News:CRH Medical reports Q1 2009 results 3Health News:LCA Hails US Court of Appeals Decision to Affirm Lower Court Ruling Tobacco Companies Guilty of Massive Fraud and Deception 2Health News:LCA Hails US Court of Appeals Decision to Affirm Lower Court Ruling Tobacco Companies Guilty of Massive Fraud and Deception 3
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    Medicine Products: